Stoke Therapeutics, Inc. (STOK) stock
STOKNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30182% above fair value
$26.81−0.12 (-0.45%)
Close on Nov 20, 2026Market cap $1.73BP/E –Yield –
Stoke Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Stoke Therapeutics's free cash flow for the twelve months ending Jun 30, 2026 was -$180.68M, down 395.5% year over year. For fiscal 2025 it was $44.92M. The highest annual figure on record is $44.92M in fiscal 2025.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.92M | – |
| FY2024 | Dec 31, 2024 | -$87.05M | – |
| FY2023 | Dec 31, 2023 | -$82.68M | – |
| FY2022 | Dec 31, 2022 | -$35.83M | – |
| FY2021 | Dec 31, 2021 | -$68.11M | – |
| FY2020 | Dec 31, 2020 | -$43.27M | – |
| FY2019 | Dec 31, 2019 | -$32.69M | – |
| FY2018 | Dec 31, 2018 | -$11.90M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$58.56M | – |
| Q1 FY2026 | Mar 31, 2026 | -$60.94M | -146.3% |
| Q4 FY2025 | Dec 31, 2025 | -$30.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$30.50M | – |
| Q2 FY2025 | Jun 30, 2025 | -$25.58M | – |
| Q1 FY2025 | Mar 31, 2025 | $131.68M | – |
| Q4 FY2024 | Dec 31, 2024 | -$23.24M | – |
| Q3 FY2024 | Sep 30, 2024 | -$21.72M | – |
| Q2 FY2024 | Jun 30, 2024 | -$17.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.58M | – |
| Q4 FY2023 | Dec 31, 2023 | -$20.88M | – |
| Q3 FY2023 | Sep 30, 2023 | -$17.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$22.64M | – |
| Q1 FY2023 | Mar 31, 2023 | -$21.52M | -168.0% |
| Q4 FY2022 | Dec 31, 2022 | -$22.78M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.09M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.61M | – |
| Q1 FY2022 | Mar 31, 2022 | $31.65M | – |
| Q4 FY2021 | Dec 31, 2021 | -$16.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.96M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.35M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.34M | – |
| Q4 FY2020 | Dec 31, 2020 | -$11.02M | – |
| Q3 FY2020 | Sep 30, 2020 | -$11.14M | – |
| Q2 FY2020 | Jun 30, 2020 | -$9.73M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.38M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.77M | – |
| Q3 FY2019 | Sep 30, 2019 | -$8.63M | – |
| Q2 FY2019 | Jun 30, 2019 | -$6.67M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.62M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.61M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.56M | – |
See a number that looks wrong?